Musculoskeletal Disorders Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The musculoskeletal disorders drugs market valued for $83,474.24 million in 2022 and is estimated to reach $126,030.22 million by 2032, exhibiting a CAGR of 4.2% from 2023 to 2032.

Musculoskeletal Disorders Drugs Market - IMG1

Musculoskeletal disorders (MSDs) affect the muscles, bones, and joints. These disorders cause pain, stiffness, and swelling in various parts of the body and they affect an ability of a person to perform daily activities. The symptoms of musculoskeletal disorders include stiff joints, swelling, and dull aches. These disorders may be caused by a variety of factors including repetitive motions, awkward postures, prolonged sitting or standing. MSDs affect people of all ages, but they are more common among the elderly and those who engage in physical activities that have stress on the musculoskeletal system, such as athletes and manual laborers. Some of the most common musculoskeletal disorders include rheumatoid arthritis, osteoporosis, osteoarthritis, and fibromyalgia.

Musculoskeletal disorders drugs are a class of medications that are used to treat conditions affecting the muscles, bones, joints of body. These drugs help to alleviate pain, inflammation, and stiffness associated with musculoskeletal disorders such as rheumatoid arthritis, osteoporosis, and fibromyalgia. There are several types of musculoskeletal drugs including analgesics, corticosteroids, disease modifying anti rheumatic drugs, and corticosteroids.

Increase in prevalence of musculoskeletal disorders such as rheumatoid arthritis osteoporosis, and ankylosing spondylitis, and surge in awareness toward availability of treatment for musculoskeletal disorders are the factors that contribute towards the growth of the market. Changes in lifestyle, such as longer working hours and increased physical activity, have resulted in a higher incidence of musculoskeletal disorders. This is anticipated to increase the demand for drugs that can effectively manage these conditions. For instance, according to Australian Institute of Health and Welfare, in 2020, it was reported that 3 in 5 individuals diagnosed with osteoarthritis. In addition, rise in geriatric population as they are more susceptible to musculoskeletal disorders, which resulted in a higher demand for drugs to manage these conditions and further drive the market growth. However, lack of access to treatment in underdeveloped countries, is expected to hamper the market growth.

Moreover, the development of new drugs for musculoskeletal disorders, including biologics and biosimilars, has improved the efficacy and safety of treatment options. This led to an increase in the demand for these drugs. In addition, increase in awareness of musculoskeletal disorders among population, which led to more patients seeking medical attention and treatment for these conditions which supports the market growth.

The global musculoskeletal disorders drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into analgesics, DMARDs, corticosteroids, and others. On the basis of route of administration, the market is bifurcated into oral, and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global musculoskeletal disorders drugs market are: AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A. Key players operating in the market have adopted product launch, and product approval as their key strategies to expand their product portfolio. For instance, in June 2022, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the musculoskeletal disorders drugs market analysis from 2022 to 2032 to identify the prevailing musculoskeletal disorders drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the musculoskeletal disorders drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global musculoskeletal disorders drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

Analgesics
DMARDs
Corticosteroids
Others

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

AbbVie Inc.
Amgen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
UCB S.A.

Product Code: A13212

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. High prevalence of musculoskeletal (MSK) disorders
  - 3.4.1.2. Surge in geriatric population across the globe
  - 3.4.1.3. Increase in number of pipeline drugs

3.4.2. Restraints
- 3.4.2.1. Lack of treatment in emerging countries

3.4.3. Opportunities
- 3.4.3.1. High growth potential in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Analgesics
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. DMARDs
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Corticosteroids
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Parenteral
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug Type
  - 7.2.5.1.3. Market size and forecast, by Route of Administration
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug Type
  - 7.2.5.2.3. Market size and forecast, by Route of Administration
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug Type
  - 7.2.5.3.3. Market size and forecast, by Route of Administration
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug Type
  - 7.3.5.1.3. Market size and forecast, by Route of Administration
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug Type
  - 7.3.5.2.3. Market size and forecast, by Route of Administration
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug Type
  - 7.3.5.3.3. Market size and forecast, by Route of Administration
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug Type
  - 7.3.5.4.3. Market size and forecast, by Route of Administration
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug Type
  - 7.3.5.5.3. Market size and forecast, by Route of Administration
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug Type
  - 7.3.5.6.3. Market size and forecast, by Route of Administration
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug Type
  - 7.4.5.1.3. Market size and forecast, by Route of Administration
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug Type
  - 7.4.5.2.3. Market size and forecast, by Route of Administration
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug Type
  - 7.4.5.3.3. Market size and forecast, by Route of Administration
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug Type
  - 7.4.5.4.3. Market size and forecast, by Route of Administration
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug Type
  - 7.4.5.5.3. Market size and forecast, by Route of Administration
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug Type
  - 7.4.5.6.3. Market size and forecast, by Route of Administration
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug Type
  - 7.5.5.1.3. Market size and forecast, by Route of Administration
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug Type
  - 7.5.5.2.3. Market size and forecast, by Route of Administration
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug Type
  - 7.5.5.3.3. Market size and forecast, by Route of Administration
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug Type
  - 7.5.5.4.3. Market size and forecast, by Route of Administration
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. AbbVie Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Amgen Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Eli Lilly and Company
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. F. Hoffmann-La Roche Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Johnson & Johnson
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Merck & Co., Inc.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Novartis AG
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Pfizer Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. UCB S.A.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance